ProMIS reaffirms Q1 2027 PRECISE-AD data timing, reports Q3 2026 results
The company said patient visits in its Phase 1b Alzheimer's trial are closing out, with cash of $44.1 million expected to fund operations through 2027.
SEC filing
9 stories
The company said patient visits in its Phase 1b Alzheimer's trial are closing out, with cash of $44.1 million expected to fund operations through 2027.
SEC filing
Ginkgo said third-quarter revenue fell 6% to $28 million while losses narrowed, and disclosed an autonomous lab sale to Novo along with new government contracts.
SEC filing (2)
The company also disclosed a CFO transition, a debt repurchase, and a $24 million CYFENDUS contract modification as it narrows its full-year outlook.
SEC filing (23)
The company stopped work on its lead NK cell therapy after two patient deaths and weak durability data, and is now reviewing strategic options including a possible sale or dissolution.
SEC filing (4)